[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
The onset of myelodysplastic syndromes (MDS) is usually around the age of 70. Despite this, most clinical trials are restricted to younger subjects. Thus, the management of elderly patients with MDS is not always optimal. Physiologically, elderly patients show characteristics that differ from those of younger patients and that condition their pharmacological treatment. In this regard, the comprehensive geriatric assessment (CGA) becomes particularly important. This document gathers conclusions from the 1(st) Meeting of Members of the Sociedad Española de Medicina Geriátrica and the Sociedad Española de Hematología y Hemoterapia, with the objective of proposing the establishment of CGA instruments to assist in the decision-making process of elderly patients with MDS. The results of this consensus document will focus on the diagnosis, prognosis, treatment and management of adverse events in this age group.
Servicio de Geriatría, Hospital Universitario La Paz, Madrid, España. pdarrieta@wanadoo.es
Jesús María
JM
López Arrieta
Raquel
R
De Paz
Albert
A
Altés
Consuelo
C
del Cañizo
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001803:Blood Transfusion; D003661:Decision Support Techniques; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D006305:Health Status Indicators; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D017262:Siderophores / Q000009:adverse effects / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D017262:Siderophores; D004921:Erythropoietin; D013792:Thalidomide; D000077269:Lenalidomide; D003676:Deferoxamine